Work

Warfarin Dose Maintenance Associated with CYP2C92 (rs1799853) and CYP2C93 (rs1057910) Gene Polymorphism in North Coastal Andhra Pradesh

Year: 2024

Type: article

Abstract: Background Deep Vein Thrombosis (DVT) is a high-risk condition that necessitates the use of oral anticoagulants for treatment. Warfarin, a common anticoagulant, exhibits varying levels of efficacy and toxicity among individuals. The CYP2C9 gene promoter polymorphism significantly influences the dosage requirements, a factor that remains underexplored in the contemporary Indian population. Objectives This study aimed to investigate the influence of CYP2C9 gene polymorphisms on warfarin dosage due to pharmacogenetic effects. Specifically, it examined the prevalence of the CYP2C9 polymorphic alleles *2 and *3 and their correlation with warfarin dosage in the South Indian Population (NCAP). Methods The study involved 96 warfarin-treated patients to determine the genotype frequency of common CYP2C9 polymorphisms. The genotypes of CYP2C92 and CYP2C93 polymorphisms were analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. A one-way analysis of variance (ANOVA) was conducted to ascertain dosage variation across genotypes. Results The study found that the frequencies of the two variations were 25.5% for CYP2C92 and 40.6% for CYP2C93. Patients with a homozygous wild-type genotype for CYP2C9 (*1/*1) required a daily warfarin dose of 4.07 ± 1.75 mg, significantly higher than the *1/*2, *1/*3 (2.93 ± 2.03 mg, p <0.0001) and *2/*2, *2/*3, and *3/*3 patients (1.54± 1.05 mg, p = 0.002). The study also revealed a distinct allelic frequency of CYP2C9 polymorphisms in the study population compared to other populations. Conclusion Given the relatively high prevalence of CYP2C9 polymorphisms in the studied population, practitioners should consider these findings to minimize the risk of bleeding when prescribing warfarin.

Source: The Open Biochemistry Journal

DOI: 10.2174/011874091x321015240703100613

Authors: Sivaraj Rangaraj, Bala Tripura Sundari Ankani

Institutions: Vinayaka Missions University, Aarupadai Veedu Medical College & Hospital

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4402007156